Tema Oncology ETF (CANC)
| Assets | $206.87M |
| Expense Ratio | 0.75% |
| PE Ratio | 19.80 |
| Shares Out | 4.98M |
| Dividend (ttm) | $0.02 |
| Dividend Yield | 0.05% |
| Ex-Dividend Date | Dec 10, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 0.93% |
| Volume | 46,753 |
| Open | 42.34 |
| Previous Close | 42.01 |
| Day's Range | 41.99 - 42.95 |
| 52-Week Low | 27.81 |
| 52-Week High | 47.00 |
| Beta | 0.72 |
| Holdings | 60 |
| Inception Date | Aug 15, 2023 |
About CANC
Fund Home PageThe Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
Top 10 Holdings
40.35% of assets| Name | Symbol | Weight |
|---|---|---|
| Revolution Medicines, Inc. | RVMD | 5.43% |
| Merck & Co., Inc. | MRK | 4.99% |
| Cogent Biosciences, Inc. | COGT | 4.74% |
| Eli Lilly and Company | LLY | 4.70% |
| Novartis AG | NOVN | 3.78% |
| Bristol-Myers Squibb Company | BMY | 3.56% |
| AbbVie Inc. | ABBV | 3.39% |
| BeOne Medicines AG | ONC | 3.38% |
| Genmab A/S | GMAB | 3.20% |
| Halozyme Therapeutics, Inc. | HALO | 3.19% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 10, 2025 | $0.01959 | Dec 11, 2025 |
| Dec 11, 2024 | $0.72827 | Dec 12, 2024 |
| Dec 13, 2023 | $0.14911 | Dec 15, 2023 |
Performance
CANC had a total return of 50.02% in the past year, including dividends. Since the fund's inception, the average annual return has been 19.23%.
News
Tema ETFs Exceeds $5bn in AUM After Three Years
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since...
Tema ETFs Surpasses $2 Billion in AUM in Under Three Years
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced that the firm has surpassed $2 billion in assets under mana...
Tema Appoints ETF Industry Leader Steve Munroe as President
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this role,...
Tema's Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (“CANC”) has surpassed $100m in asset...
Tema Surpasses $1bn AUM Two Years After Launch, Strengthens Team With Key Growth Hires
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), has surpassed $1 billion in assets under management (AUM) in just two years since...
Tema Launches Two Innovative, Active ETF Thematic Strategies: Oncology & Global Royalties
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”) launches two innovative and actively managed thematic ETF offerings: the Oncology ETF (CANC) and the Global Royalties ETF (ROYA). These strategies are the...